Shocker: Fat Women Stop Taking Weight Loss Drugs Like Wegovy Within a Year

You can’t fix personal problems with drugs. This is something that is widely accepted when it comes to fentanyl or whatever other extreme narcotic, but with other personal problems, we have decided drugs may well be the solution.

A fat person is not going to stop being fat because you put them on drugs. If they take the drugs and stop being fat, it is incidental.

Most of them remain fat. We have this data now.


Only about one-third of patients prescribed a popular weight-loss drug like Novo Nordisk’s Wegovy were still taking it a year later, while total healthcare costs for the group rose sharply, according to an analysis of U.S. pharmacy claims shared with Reuters.

The annual cost of overall care for patients prior to taking Wegovy or a similar drug was $12,371, on average, according to the analysis. The full-year cost after starting the medication jumped by 59% to $19,657, on average.

The costs for a similar control group of patients not taking the drugs decreased by 4% over the same period. The mean age of patients included in the analysis was 47 and 81% were female.

Medicines such as Wegovy can cost more than $1,000 per month, and any improvement in health and subsequent reduction in medical costs is not likely to occur quickly.

This analysis points to the fact that there can be a lot of spending on people that are not likely to reap any long-term health benefits,” said Khrysta Baig, a health policy researcher at Vanderbilt University who reviewed the findings for Reuters.

Overall, 32% of the patients were still taking the medicine for weight loss a year after their initial prescription. All the patients had insurance coverage for GLP-1 drugs, and the results did not differ materially based which of the drugs was prescribed, Prime said.

Patrick Gleason, Prime’s assistant vice president for health outcomes and a co-author of the analysis, said this real-world data suggests a substantial drop in adherence compared to what was reported in clinical trials. In trials with adults, Novo found that 6.8% of patients taking Wegovy discontinued treatment due to gastrointestinal problems and other adverse events.

“The majority of patients aren’t getting the value of the product and there’s waste, especially with an expensive therapy,” Gleason said. “I was a little bit surprised by the persistency rate.”

The government is paying for these drugs.

How does that even make any sense?

The government should put them in fat camps.

Or worse, quite frankly.